Stay updated on Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.

Sign up to get notified when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The website has been updated to version v2.10.0, adding 6 more interventions/treatments, 5 more study numbers, and noting that the study now has 244 locations, while the previous version v2.9.7 has been removed.
    Difference
    0.2%
    Check dated 2024-07-23T14:50:19.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.0%
    Check dated 2024-07-16T06:35:04.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has recently changed from v2.9.5 to v2.9.6. This change represents an update or modification to the content of the web page.
    Difference
    0.0%
    Check dated 2024-07-02T12:33:30.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value Revision: v2.9.3 has recently changed to Revision: v2.9.5. This change represents an update in the study record details and information related to a clinical trial for the treatment of breast cancer using pembrolizumab and chemotherapy.
    Difference
    0.0%
    Check dated 2024-06-27T09:39:09.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value Revision: v2.9.1 has recently changed to Revision: v2.9.3. This change represents an update in the study record details and outcomes for a clinical trial evaluating the efficacy and safety of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for the treatment of early-stage breast cancer.
    Difference
    0.0%
    Check dated 2024-06-26T08:23:45.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Difference
    35%
    Check dated 2024-06-25T07:58:12.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.